• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION INTELLANAV CATHETERS; catheter, percutaneous, cardiac ablation, for treatment of atrial flutter

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION INTELLANAV CATHETERS; catheter, percutaneous, cardiac ablation, for treatment of atrial flutter Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Cardiac Tamponade (2226)
Event Date 06/07/2022
Event Type  Injury  
Event Description
Per literature review, it was reported that: at gunma prefectural cardiovascular center from september 2019 to november 2020, 157 patients were enrolled to this study who were scheduled to undergo an initial extensive pvi of af guided by the rhythmia system, using the intellanav mifi open-irrigated ablation catheter.All patients underwent transesophageal and or intracardiac echocardiography to rule out any intracardiac thrombi before the ablation procedure and contrast-enhanced computed tomography (ct) or plain magnetic resonance (mr) imaging for assessment of the pulmonary vein and left atrium anatomy.During the ablation procedure, the activated clotting time was maintained between 300 and 400 s by a continuous and additional bolus heparin infusion.All patients received deep conscious sedation throughout the procedure using propofol or dexmedetomidine, and pentazocine.The catheter was introduced into the left atrium through three transseptal sheaths (non-boston scientific brand).The pvo started in an order from right pulmonary veins (rpv) to left pulmonary veins (lpv) in 76 patients and from the lpvs to rpvs in 81 patients and was successfully completed in all patients.A total of 28 patients underwent additional ablation procedures other than the pvi and cavo tricuspid isthmus linear ablation.Procedure-related complications occurred in four patients: a cardiac tamponade in one, which could be managed with percutaneous pericardial drainage, gastric hypomotility in two, which spontaneously resolved, and a femoral hematoma in one, which could be managed with a local pressure application.All endocardial residual and reconnected gaps were successfully eliminated with rf applications at the gap sites on the initial pvi lines.Nakamura k, sasaki t, minami k, et al., prevalence, characteristics, and predictors of endocardial and non-endocardial conduction gaps during local impedance-guided extensive pulmonary vein isolation of atrial fibrillation with high-resolution mapping.J cardiovasc electrophysiol.2021;32: 2045-2059.Https://doi.Org/10.1111/jce.15152.
 
Manufacturer Narrative
It was indicated that the device will not be returned for evaluation.If there is any further relevant information obtained, a supplemental medwatch will be filed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INTELLANAV CATHETERS
Type of Device
catheter, percutaneous, cardiac ablation, for treatment of atrial flutter
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC DE COSTA RICA S.R.L.
302 parkway, global park
la aurora, heredia
CS  
Manufacturer Contact
timothy degroot
4100 hamline avenue north
dc a330
saint paul, MN 55112
6515826168
MDR Report Key18194318
MDR Text Key328825114
Report Number2124215-2023-66033
Device Sequence Number1
Product Code OAD
Combination Product (y/n)N
Reporter Country CodeJA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 11/22/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/22/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/17/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age67 YR
Patient SexMale
-
-